Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Phase 4

Recruiting

Conditions: Hepatocellular Carcinoma
Hepatocellular Cancer

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2022-01-11

Last Posted Date: 2023-02-01

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 24

Registration Number: NCT05185505

Locations: 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Phase 2

Active, not recruiting

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Atezolizumab
Drug: Derazantinib

First Posted Date: 2022-01-03

Last Posted Date: 2024-07-24

Lead Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Target Recruit Count: 27

Registration Number: NCT05174650

Locations: 🇩🇪
MVZ am Oskar-Helene Heim Berlin, Berlin, Germany
🇩🇪
Universitätsmedizin Mannheim, Mannheim, Germany
🇩🇪
Vivantes Klinikum Berlin Friedrichshain, Berlin, Germany

and more 14 locations

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2021-12-29

Last Posted Date: 2024-11-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 179

Registration Number: NCT05171777

Locations: 🇨🇦
Ottawa Hospital, Ottawa, Ontario, Canada
🇮🇹
Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇰🇷
Chungbuk National University Hospital, Cheongju-si, Korea, Republic of

and more 36 locations

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Phase 2

Recruiting

Conditions: Advanced Cancer
Solid Tumor
Haematological Malignancy

Interventions: Drug: Cobimetinib
Drug: Trastuzumab+Pertuzumab
Drug: Trametinib
Drug: Dabrafenib+Trametinib
Drug: Abemaciclib
Drug: Tepotinib
Drug: Dabrafenib
Drug: Pemigatinib
Drug: Regorafenib
Drug: Alectinib
Drug: Vismodegib
Drug: Entrectinib
Drug: Atezolizumab
Drug: Vemurafenib
Drug: Apalutamide

First Posted Date: 2021-12-16

Last Posted Date: 2024-07-15

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 250

Registration Number: NCT05159245

Locations: 🇫🇮
Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland
🇫🇮
Kuopio University Hospital, Kuopio, Finland
🇫🇮
Oulu University Hospital OYS Cancer Center, Oulu, Finland

and more 2 locations

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Phase 1

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: [177Lu]Lu-DOTA-TATE
Drug: Atezolizumab
Drug: [68Ga]Ga-DOTA-TATE
Other: Carboplatin
Other: Etoposide

First Posted Date: 2021-12-02

Last Posted Date: 2024-10-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT05142696

Locations: 🇺🇸
Georgetown University Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇬🇧
Novartis Investigative Site, Guildford, Surrey, United Kingdom

and more 1 locations

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Colorectal Neoplasms

Interventions: Drug: GRT-C901
Drug: GRT-R902
Drug: Atezolizumab
Drug: Ipilimumab
Drug: Fluoropyrimidine plus leucovorin
Drug: Bevacizumab

First Posted Date: 2021-12-02

Last Posted Date: 2023-12-22

Lead Sponsor: Gritstone bio, Inc.

Target Recruit Count: 700

Registration Number: NCT05141721

Locations: 🇺🇸
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Advanced Research (Oncology & Hemotology Associates of West Broward), Tamarac, Florida, United States
🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States

and more 40 locations

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2021-11-12

Last Posted Date: 2024-12-16

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 80

Registration Number: NCT05118724

Locations: 🇩🇪
Westdeutsches Tumorzentrum, Essen, Germany

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: RO7247669 600 mg
Drug: RO7247669 2100 mg
Drug: Atezolizumab
Drug: Nivolumab
Drug: Ipilimumab
Drug: Tiragolumab

First Posted Date: 2021-11-10

Last Posted Date: 2024-10-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 110

Registration Number: NCT05116202

Locations: 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇺🇸
The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
🇮🇹
Ospedale S.Maria della Misericordia, Perugia, Umbria, Italy

and more 18 locations

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Atezolizumab
Drug: Pemetrexed
Drug: Bevacizumab
Drug: Paclitaxel
Drug: Enzalutamide

First Posted Date: 2021-11-09

Last Posted Date: 2024-12-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT05112965

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳
Tianjin Cancer Hospital, Tianjin, China
🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China

and more 16 locations

Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.

Phase 1

Recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: MTL-CEBPA
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2021-10-28

Last Posted Date: 2021-10-28

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 33

Registration Number: NCT05097911

Locations: 🇸🇬
National University Hospital, Singapore, Singapore

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy